Patents by Inventor Raphaël Darteil

Raphaël Darteil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment using EYP001
    Patent number: 12551480
    Abstract: The present invention relates to a method of treatment with an FXR agonist allowing to decrease pruritus and improve efficacy.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: February 17, 2026
    Assignee: ENYO PHARMA
    Inventors: Jacky Vonderscher, Elise Roy, Raphaël Darteil, Pietro Scalfaro
  • L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF
    Publication number: 20250019358
    Abstract: An L-lysine salt of 4-chloro-5-[4-(2.6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and forms thereof are provided. Also provided are pharmaceutical or veterinary compositions comprising this L-lysine salt and their use for treating a number of diseases.
    Type: Application
    Filed: July 3, 2024
    Publication date: January 16, 2025
    Inventors: RAPHAËL DARTEIL, JACKY VONDERSCHER, DIANE SAMPSON, NICOLAS PHILIPPON, JOËL VACUS, JULIEN LEROUDIER, SANDRA WERNER, FRANÇOISE RICHARD-TIBERGHIEN
  • L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF
    Publication number: 20250019370
    Abstract: An L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and forms thereof are provided. Also provided are pharmaceutical or veterinary compositions comprising this L-lysine salt and their use for treating a number of diseases.
    Type: Application
    Filed: July 3, 2024
    Publication date: January 16, 2025
    Inventors: RAPHAËL DARTEIL, JACKY VONDERSCHER, DIANE SAMPSON, NICOLAS PHILIPPON, JOËL VACUS, JULIEN LEROUDIER, SANDRA WERNER, FRANÇOISE RICHARD-TIBERGHIEN
  • NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20240410010
    Abstract: The invention relates to a novel method for the diagnosis of non-alcoholic steatohepatitis (NASH), and for classifying a subject as a potential receiver of a treatment for NASH.
    Type: Application
    Filed: August 29, 2024
    Publication date: December 12, 2024
    Inventors: RAPHAËL DARTEIL, GENEVIÈVE CORDONNIER, JOHN BROZEK, EMILIE PRACA, FOUAD BEN SUDRIK
  • Non-invasive diagnostic of non-alcoholic steatohepatitis
    Patent number: 12104209
    Abstract: The invention relates to a novel method for the diagnosis of non-alcoholic steatohepatitis (NASH), and for classifying a subject as a potential receiver of a treatment for NASH.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: October 1, 2024
    Assignee: GENFIT
    Inventors: Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof
    Patent number: 12030861
    Abstract: An L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and forms thereof are provided. Also provided are pharmaceutical or veterinary compositions comprising this L-lysine salt and their use for treating a number of diseases.
    Type: Grant
    Filed: July 13, 2023
    Date of Patent: July 9, 2024
    Assignee: ENYO PHARMA
    Inventors: Raphaël Darteil, Jacky Vonderscher, Diane Sampson, Nicolas Philippon, Joël Vacus, Julien Leroudier, Sandra Werner, Françoise Richard-Tiberghien
  • STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT
    Publication number: 20240216364
    Abstract: The present invention relates to a combination of a FXR agonist and a TLR3 agonist having a synergistic effect and its use for the treatment of disease and disorders.
    Type: Application
    Filed: April 28, 2022
    Publication date: July 4, 2024
    Inventors: RAPHAËL DARTEIL, DAVID DURANTEL
  • THIOPHENE DERIVATIVES FOR USE IN TREATING PORTAL INFLAMMATION AND FIBROSIS
    Publication number: 20240156778
    Abstract: The present invention relates to a compound of formula (I) for use in a method for treating hepatic portal/periportal inflammation, optionally hepatic portal/periportal fibrosis.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 16, 2024
    Inventors: RAPHAËL DARTEIL, ERIC MELDRUM, JACKY VONDERSCHER
  • SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION
    Publication number: 20240100125
    Abstract: The present invention relates to a synergistic combination of an FXR agonist and interferon for the treatment of hepatitis B.
    Type: Application
    Filed: January 13, 2022
    Publication date: March 28, 2024
    Inventors: RAPHAËL DARTEIL, PIETRO SCALFARO, JACKY VONDERSCHER, ELISE ROY, DAVID DURANTEL
  • THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS
    Publication number: 20230321033
    Abstract: The present invention relates to a method for treating renal fibrosis.
    Type: Application
    Filed: August 5, 2021
    Publication date: October 12, 2023
    Inventors: RAPHAËL DARTEIL, STÉPHANIE LE CORRE, ERIC MELDRUM, FABIOLA TERZI, JACKY VONDERSCHER
  • METHOD FOR TREATING CHRONIC KIDNEY DISEASES
    Publication number: 20230165853
    Abstract: The present invention relates to a method for treating chronic kidney diseases.
    Type: Application
    Filed: January 13, 2022
    Publication date: June 1, 2023
    Inventors: FABIOLA TERZI, RAPHAËL DARTEIL, PIETRO SCALFARO, JACKY VONDERSCHER, HUGO GIRMA
  • USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS
    Publication number: 20230060715
    Abstract: The present invention relates to the use of a farnesoid X receptor (FXR) agonist for the treatment of hepatitis D infection.
    Type: Application
    Filed: January 14, 2021
    Publication date: March 2, 2023
    Inventors: RAPHAËL DARTEIL, JULIE LUCIFORA, DAVID DURANTEL, CHRISTOPHE RAMIERE, BENOÎT LACOMBE, VINCENT LOTTEAU, PATRICE ANDRE
  • METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20220411874
    Abstract: The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.
    Type: Application
    Filed: June 24, 2022
    Publication date: December 29, 2022
    Applicant: Genfit
    Inventors: Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • SYNERGISTIC EFFECT OF EYP001 AND IFN FOR THE TREATMENT OF HBV INFECTION
    Publication number: 20220313690
    Abstract: The present invention relates to a synergistic combination of EYP001 and interferon for the treatment of hepatitis B.
    Type: Application
    Filed: July 17, 2020
    Publication date: October 6, 2022
    Inventors: JACKY VONDERSCHER, ELISE ROY, RAPHAËL DARTEIL, PIETRO SCALFARO
  • IMPROVED TREATMENT USING EYP001
    Publication number: 20220249469
    Abstract: The present invention relates to a method of treatment with an FXR agonist allowing to decrease pruritus and improve efficacy.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 11, 2022
    Inventors: JACKY VONDERSCHER, ELISE ROY, RAPHAËL DARTEIL, PIETRO SCALFARO
  • METHOD FOR DECREASING ADVERSE-EFFECTS OF INTERFERON
    Publication number: 20220241376
    Abstract: The present invention relates to a method for decreasing adverse-effects of interferon and to new compositions and methods of treatment.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 4, 2022
    Inventors: JACKY VONDERSCHER, ELISE ROY, RAPHAËL DARTEIL, PIETRO SCALFARO
  • Methods for diagnosing and evaluating non-alcoholic steatohepatitis
    Patent number: 11371098
    Abstract: The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: June 28, 2022
    Assignee: Genfit
    Inventors: Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20180265924
    Abstract: The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.
    Type: Application
    Filed: September 14, 2016
    Publication date: September 20, 2018
    Applicant: Genfit
    Inventors: Raphaël Darteil, Geneviève Cordonnier, Brozek Brozek, Emilie Praca, Fouad Ben Sudrik
  • USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS
    Publication number: 20120252725
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Application
    Filed: November 26, 2010
    Publication date: October 4, 2012
    Inventors: Raphaël Darteil, Rémy Hanf, Dean Hum
  • Acylated aminopropanediols and analogues and therapeutic uses thereof
    Patent number: 7253296
    Abstract: The invention relates to novel acylated aminopropanediols and the nitrogen and sulfur analogues thereof, pharmaceutical compositions comprising same, therapeutic uses thereof, in particular for the treatment of cerebral ischemia. The invention also provides a method of preparing said derivatives.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: August 7, 2007
    Assignee: Genfit
    Inventors: Raphaël Darteil, Karine Caumont-Bertrand, Jamila Najib